[Progress of therapy in patients with multiple sclerosis].
Kümpfel
Tania
T
Institut für Klinische Neuroimmunologie, Klinikum der Universitüt München, Grosshadern-Ludwig-Maximilians-Universität München. tania.kuempfel@med.uni-muenchen.de
Havla
Joachim
J
Hohlfeld
Reinhard
R
D015761:4-Aminopyridine / Q000008:administration & dosage / Q000009:adverse effects; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D001921:Brain / Q000473:pathology; D017338:Cladribine / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D000068876:Fingolimod Hydrochloride; D008279:Magnetic Resonance Imaging; D020528:Multiple Sclerosis, Chronic Progressive / Q000175:diagnosis / Q000188:drug therapy*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D011409:Propylene Glycols / Q000008:administration & dosage / Q000009:adverse effects; D000069283:Rituximab; D013110:Sphingosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000069442:Natalizumab; D011409:Propylene Glycols; D017338:Cladribine; D000069283:Rituximab; D015761:4-Aminopyridine; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine